脑脊髓液中的 PCSK9 浓度在阿尔茨海默病中并未特异性增加。

PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease.

机构信息

Department of Neurology, CHU de Nantes, Nantes, France.

Department of Biochemistry, CHU de Nantes, Nantes, France.

出版信息

J Alzheimers Dis. 2018;62(4):1519-1525. doi: 10.3233/JAD-170993.

DOI:10.3233/JAD-170993

PMID:29562508

Abstract

The role of PCSK9 in Alzheimer's disease (AD) is controversial. We compared cerebrospinal fluid (CSF) PCSK9 concentrations in 36 AD and 31 non-AD patients. CSF PCSK9 levels did not differ between AD and non-AD groups (2.80 versus 2.62 ng/mL). However, PCSK9 CSF levels were increased in AD and non-AD patients with other neurodegenerative process (non-AD ND, n = 20) compared to patients without neurodegenerative disorders (non-ND, n = 11): 2.80 versus 2.30 (p < 0.005) and 2.83 versus 2.30 ng/mL (p = NS), respectively. CSF PCSK9 were positively correlated with AD biomarkers (Aβ1-42, T-tau, and P-tau). PCSK9 concentrations in CSF are increased in neurodegenerative disorders rather than specifically in AD.

摘要

PCSK9 在阿尔茨海默病（AD）中的作用存在争议。我们比较了 36 名 AD 患者和 31 名非 AD 患者的脑脊液（CSF）PCSK9 浓度。AD 和非 AD 组之间 CSF PCSK9 水平没有差异（2.80 与 2.62ng/mL）。然而，与无神经退行性疾病（非 ND，n=11）患者相比，具有其他神经退行性过程的 AD 和非 AD 患者（非 AD ND，n=20）的 CSF PCSK9 水平升高：2.80 与 2.30（p<0.005）和 2.83 与 2.30ng/mL（p=NS）。CSF PCSK9 与 AD 生物标志物（Aβ1-42、T-tau 和 P-tau）呈正相关。CSF 中的 PCSK9 浓度在神经退行性疾病中升高，而不是在 AD 中特异性升高。